Fractyl Health (GUTS) Enterprise Value (2023 - 2026)
Fractyl Health's (GUTS) quarterly Enterprise Value came in at -$63.2 million in Q1 2026, down 50.12% YoY from -$126.7 million in Q1 2025, and up 22.49% on a QoQ basis from -$81.5 million in Q4 2025.
Fractyl Health (GUTS) Enterprise Value (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Enterprise Value data on file, last reported at -$63.2 million in Q1 2026.
- Quarterly Enterprise Value fell 50.12% year-over-year to -$63.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$63.2 million (down 50.12% YoY) and the FY2025 annual result came in at -$81.5 million, down 20.86% from the prior year.
- Enterprise Value advanced to -$63.2 million in Q1 2026, from -$81.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$22.3 million in Q2 2025 to a low of -$121.8 million in Q1 2024.
- A 4-year average of -$69.7 million and a median of -$72.6 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value plunged 101.24% — and 2025, when it surged 78.31%.
- Tracing GUTS's Enterprise Value over 4 years: stood at -$33.5 million in 2023, then sank by 101.24% to -$67.5 million in 2024, then fell by 20.86% to -$81.5 million in 2025, then grew by 22.49% to -$63.2 million in 2026.
- The last three Enterprise Value figures came in at -$63.2 million (Q1 2026), -$81.5 million (Q4 2025), and -$77.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | 2.12 Bn |
| 10 | Fractyl Health | 114.37 Mn | 114.37 Mn | - | -47.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.14 Mn |
| Mar 31, 2026 | -63.20 Mn |
| Dec 31, 2025 | -81.54 Mn |
| Sep 30, 2025 | -77.66 Mn |
| Jun 30, 2025 | -22.29 Mn |
| Mar 31, 2025 | -42.10 Mn |
| Dec 31, 2024 | -67.46 Mn |
| Sep 30, 2024 | -84.66 Mn |
| Jun 30, 2024 | -102.75 Mn |
| Mar 31, 2024 | -121.76 Mn |
| Dec 31, 2023 | -33.52 Mn |